Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in China / NCT06872034
Recruiting Not applicable

The Efficacy and Safety of Venostan in Promoting Postoperative Swelling Reduction in Patients With Ankle Fractures

NCT06872034 · tracked via the Priya Life Science China tracker
Sponsor
Beijing Jishuitan Hospital
Phase
Not applicable
Started
2025-04-16
Last updated
2025-07-16

Condition(s) studied

Swelling/ Edema

Investigational drug(s) / intervention(s)

Venostasin (horse chestnut seed extract tablets)standard treatment

Venostasin (horse chestnut seed extract tablets): Venostasin (horse chestnut seed extract tablets) ，twice daily, 400 mg per dose, for 14 days

standard treatment: standard treatment

Study summary

This study is a multicenter, open-label, randomized controlled trial planned to enroll patients with ankle fractures who meet the inclusion and exclusion criteria and are scheduled to undergo internal fixation surgery from the emergency and inpatient wards of multiple hospitals. General and disease-related data will be collected. All eligible patients must voluntarily sign an informed consent form after understanding and accepting the study. Successfully recruited participants will undergo internal fixation surgery at a scheduled time and then be randomly assigned to either the Venostan (horse chestnut seed extract tablet) group or the conventional treatment group. They will receive the corresponding treatments according to the study protocol. Follow-up assessments will include changes in ankle circumference, ankle range of motion, scale evaluation results, laboratory test results, and adverse events. The study aims to evaluate the effects of Venostasin in patients with ankle fractures undergoing internal fixation surgery, exploring its potential to promote postoperative reduction of ankle swelling, enhance early joint function recovery, and investigate its safety in postoperative fracture management.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * ≥18 year old, no gender restriction; * Diagnosed with ankle fracture confirmed by imaging data, AO classification: ---AO-43, AO-44-F3, AO-44; * Scheduled to undergo open reduction and internal fixation surgery; * Voluntary signing of the informed consent form. Exclusion Criteria: * Pregnant or lactating women; * With contraindications to surgery; * With other severe combined injuries or soft tissue infections; * Severe multiple trauma: Injury Severity Score (ISS) \> 16; * With concurrent fractures of the spine, pelvis, or ipsilateral or contralateral lower limbs; * Pathological fractures; * With peripheral vascular disease or deep vein thrombosis (DVT); * With severe impairment of heart, lung, liver, or kidney function or abnormal coagulation function; * Unable to walk independently before the injury; * With pre-existing lower limb edema (e.g., due to liver cirrhosis, kidney disease, etc.) before the injury; * With mental disorders or hyperalgesia; * Allergic to any component of the investigational drug; * Any contraindications that limit clinical evaluation and treatment of the patient; * Deemed unsuitable for inclusion in this study by the investigator.

Primary outcome measure(s)

  • Change in ankle circumference at 6 days postoperatively compared to baseline — from enrollment to the 6th day postoperation
    Defined as the change in ankle circumference measured using the figure-of-eight method on postoperative day 6 (after 5 days of Venostan treatment) compared to the ankle circumference measured on postoperative day 2 (before the first dose of Venostan)

Trial sites (1)

FacilityCityRegionStatus
Beijing Jishuitan Hospital Beijing China Recruiting

More Beijing Jishuitan Hospital trials in China

Chinese Second Hip Fracture Evaluation Recruiting
Robot-Assisted Closed Reduction and Internal Fixation for Distal Femoral Fractures Recruiting
A RCT of Collagen Scaffold for the Repair of Talus Cartilage Injury Enrolling by invitation
Robot-Assisted Closed Reduction and Internal Fixation for Extra-Articular Distal Tibial Fractures Recruiting
Does Medial Raw Anchor Necessary During Tendon Repair Combined With Microfracture Enrolling by invitation
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06872034 on ClinicalTrials.gov ↗ ← All trials in China